iCAD (NASDAQ:ICAD) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of iCAD (NASDAQ:ICAD) from a sell rating to a hold rating in a report issued on Thursday.

iCAD Stock Performance

ICAD opened at $1.54 on Thursday. iCAD has a 1 year low of $1.18 and a 1 year high of $2.65. The company’s 50 day simple moving average is $1.72 and its 200 day simple moving average is $1.54. The stock has a market capitalization of $40.87 million, a PE ratio of -11.85 and a beta of 1.47.

Hedge Funds Weigh In On iCAD

A number of large investors have recently modified their holdings of ICAD. Virtu Financial LLC increased its holdings in iCAD by 55.6% in the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after purchasing an additional 7,604 shares in the last quarter. Perritt Capital Management Inc increased its position in shares of iCAD by 14.2% during the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after acquiring an additional 19,917 shares during the last quarter. Essex LLC acquired a new position in shares of iCAD in the third quarter worth about $216,000. Finally, Perritt Capital Management Inc. boosted its holdings in iCAD by 7.5% in the first quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after purchasing an additional 9,717 shares during the last quarter. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.